In December 2024, 30-year-old Spencer Laird of South Carolina learned his colorectal cancer had returned and spread to his lungs after a routine follow-up scan. Doctors found 13 lung tumors, the largest roughly the size of a golf ball, and gave a prognosis of about two years even with treatment. Laird and his wife, CarleyAnn, pursued alternatives and he enrolled in a Duke University immunotherapy trial in February 2025. Within months scans showed dramatic tumor shrinkage and by late 2025 his disease had fallen from 13 measurable lung lesions to three, with the largest now about 0.6 millimeters.
- Patient and timeline: Spencer Laird first noticed symptoms at 25; recurrence and lung metastases were documented in December 2024; he joined the Duke trial in February 2025.
- Extent of spread: Initial staging identified 13 lung tumors; one lesion measured approximately the size of a golf ball at detection.
- Trial details: The single-arm study enrolled 15 patients; participants receive immunotherapy every two weeks and undergo imaging every six to eight weeks.
- Response seen: Laird’s tumor count fell from 13 to 3 and the largest lesion reduced to about 0.6 millimeters by December 2025.
- Prior evidence: When used after multiple chemotherapies, immunotherapy produced objective responses in about 25% of patients and disease control in 70% in earlier studies cited by investigators.
- Conventional outcomes: For microsatellite-stable colorectal cancer, chemotherapy typically controls disease for at least six months in roughly 80 to 90% of patients, according to outside experts.
- Toxicity and quality of life: Laird experienced rashes, headaches, nausea and dizziness early in treatment, but side effects largely subsided by late spring 2025.
Background
Colorectal cancer that is microsatellite-stable (MSS) represents the large majority of colorectal tumors and is usually treated with chemotherapy and, when appropriate, radiation and surgery. MSS tumors historically respond less well to single-agent immunotherapy than microsatellite-instability high (MSI-H) cancers, which is why immune-based drugs have generally been reserved for later lines of therapy in MSS disease. Standard systemic chemotherapy can temporarily control tumor burden in many MSS patients, but long-term durable remissions are uncommon.
Clinical investigators at major cancer centers have begun testing whether moving immunotherapy earlier in the treatment sequence can improve outcomes for selected patients. Those trials typically exclude patients whose disease threatens immediate organ function, because delaying chemotherapy may pose short-term risks. The Duke trial that enrolled Laird tests immunotherapy given as an initial systemic treatment for MSS colorectal cancer, a strategy that challenges existing paradigms.
Main Event
After his December 2024 scan showed pulmonary metastases, Laird and his wife reviewed options. They applied to several trials, and Laird entered a Duke University study in February 2025 that administers an immune checkpoint inhibitor every two weeks and monitors response with scans every six to eight weeks. Investigators describe an intended safety net: if a patient shows clear disease progression they switch to chemotherapy.
Early on, Laird had one of the most pronounced radiologic responses in the cohort. Sequential imaging documented steady shrinkage of lung masses over months, turning large measurable nodules into submillimeter findings for the largest lesion. Clinicians emphasize that this outcome is exceptional for MSS metastatic colorectal cancer and that longer follow-up will be required to assess durability.
Physically, Laird reported temporary side effects—skin rash, headaches and gastrointestinal upset—that eased by late spring 2025. He continues to receive biweekly infusions at Duke and remains under close surveillance. Investigators plan to publish the full trial results in April 2026, and they are analyzing patterns among responders and nonresponders to identify potential predictive biomarkers.
Analysis & Implications
This case illustrates a potentially important shift in thinking about immunotherapy for MSS colorectal cancer, but it is essential to treat a single-patient dramatic response as hypothesis-generating rather than definitive. If reproducible in larger, randomized trials, front-line immunotherapy could alter treatment sequencing and expand non-chemotherapy options for patients who prioritize quality of life. However, broad adoption would require evidence of durable survival benefit and acceptable safety compared with established chemotherapy regimens.
Researchers will need to determine which patients are most likely to benefit. Biomarker discovery is central: genomic, immunologic and microenvironmental features may help predict response. Investigators already plan subgroup analyses and correlative studies from the trial to seek signals that distinguish responders like Laird from patients with minimal benefit.
There are practical and ethical trade-offs to consider. Administering immunotherapy first can spare some patients from chemotherapy toxicity, but it may delay a proven, effective therapy for others. Trial design going forward should balance rapid access to novel approaches with safeguards—such as early imaging and preplanned switch criteria—to minimize risk for participants whose disease worsens.
Comparison & Data
| Context | Reported metric |
|---|---|
| Initial lung tumor count (Laird) | 13 lesions |
| Largest tumor at detection | ~golf-ball size; later 0.6 mm |
| Trial enrollment | 15 patients |
| Immunotherapy as late-line (prior data) | ~25% objective responses; 70% disease control |
| Chemo disease control (MSS colorectal) | ~80–90% control for at least 6 months |
The table summarizes key numeric comparisons reported by investigators and outside experts. While chemotherapy retains a well-established short-term disease control rate for many MSS patients, the current trial suggests that a subset may achieve pronounced and rapid tumor regressions with immunotherapy used earlier. The degree to which those remissions translate into prolonged survival remains to be proven.
Reactions & Quotes
Investigators and outside experts emphasize cautious optimism while noting the need for more data.
It is proof of concept that you can use immunotherapy front line and see activity, but larger studies are required to define who benefits most.
Michael J. Overman, MD — MD Anderson Cancer Center (academic oncologist)
The lead investigator at Duke described the team’s surprise at the magnitude of some responses and highlighted plans for correlative science.
We are asking whether certain patients can safely receive immunotherapy first and whether combining approaches might improve outcomes further.
Nicholas DeVito, MD — Duke University (gastrointestinal oncologist, trial investigator)
Laird and his family framed the change in practical, personal terms: relief at regained time and focus on daily life as the treatment produced marked shrinkage.
Looking at where it started and where it is now, it is unbelievable; it feels like a miracle.
Spencer Laird — patient
Unconfirmed
- Durability of Laird’s remission beyond the current follow-up is unknown and unproven as a cure.
- Which specific biomarkers, if any, predict the powerful responses seen in this patient remain under investigation.
- Whether the trial’s outcomes will generalize to a broader MSS metastatic colorectal population is not yet confirmed pending full results.
- The full peer-reviewed trial manuscript is scheduled for publication in April 2026; details and long-term endpoints are pending.
Bottom Line
Spencer Laird’s experience highlights an important signal: immunotherapy given up front can, in at least some MSS colorectal cancer patients, produce deep and rapid tumor regressions. That outcome challenges the assumption that chemotherapy must precede immune agents in most MSS cases, but it is not sufficient by itself to change standard practice. Clinicians and patients should view such reports as promising early evidence that requires confirmation through larger, controlled trials with long-term follow-up.
For patients and families confronting metastatic MSS colorectal cancer, the case underscores the potential value of clinical trial enrollment and rigorous monitoring. Over the next 12–24 months, published trial data, biomarker analyses and additional studies will determine whether this approach can be safely expanded, which patients stand to benefit most, and how long remissions may last.
Sources
- CBS News — news report summarizing the patient story and trial details (media).
- Duke Health — institutional information from the trial site and physician investigators (institutional/clinical).
- The University of Texas MD Anderson Cancer Center — expert commentary provided by outside academic oncologists (academic center).